Monitor this situation.

Unsubscribe anytime.

[SITUATION] · [QUIET] · [HEALTH]

2 clusters · 8 sources · 7 days · First seen 17 days ago · Last updated 11 days ago

Retatrutide clinical trials for sleep apnea

Overview

Clinical trials, specifically the TRIUMPH-1-OSA and TRIUMPH-2-OSA Phase 3 studies, have indicated that the investigational weight-loss medication retatrutide may significantly reduce the severity of obstructive sleep apnea (OSA).

Results published in the New England Journal of Medicine showed that participants receiving once-weekly injections of retatrutide experienced a greater reduction in the apnea-hypopnea index (AHI) compared to a placebo group. In participants without type 2 diabetes, AHI reductions ranged from approximately 23 to 34 events per hour, while those with type 2 diabetes saw reductions between 19 and 25 events per hour. Additionally, participants experienced weight loss between 12% and 22%.

Broader research into sleep apnea highlights the condition’s interaction with diabetes, noting that sleep apnea may increase risks for cardiovascular dysfunction and chronic kidney disease. The potential for oral medications like retatrutide to serve as alternatives to CPAP masks is being explored as part of new therapeutic approaches.

Entities

Carlos Núñez · Eli Lilly · Premium Medical Circle · ResMed

Claims

What the coverage asserts, and how many sources carry each claim.

[● 2 SOURCES] Obstructive sleep apnea can affect individuals who do not fit the classic risk profile.
[● 2 SOURCES] Snoring and daytime fatigue are potential signs of obstructive sleep apnea.
[○ 1 SOURCE] Two Phase 3 studies of Retatrutide showed a reduction in breathing pauses.
[○ 1 SOURCE] Sleep apnea increases the risk of microvascular complications in patients with diabetes.
[○ 1 SOURCE] Nighttime hypoxia levels may predict cardiovascular events in diabetics more effectively than the apnea-hypopnea index.

Timeline

11 days ago

[HEALTH] 4 sources
Sleep apnea research highlights new therapies and health risks
Medical experts and studies highlight the risks of undiagnosed sleep apnea, its link to diabetes complications, and emerging treatments like Retatrutide.
17 days ago

[HEALTH] 4 sources
Retatrutide reduces sleep apnea severity in clinical trials
Clinical trials for the investigational drug retatrutide show significant reductions in sleep apnea severity and substantial weight loss in adults with obesity.

Sources

ad-hoc-news.de · adtelligent.com · bestratedhealth.com · fehmarn24.de · healthworkscollective.com · hna.de · merkur-online.de · world-today-journal.com